您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Spantide I TFA
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Spantide I TFA
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品介绍
Spantide I TFA 是substance P 的类似物,是选择性的神经激肽-1 受体 (NK1receptor) 的拮抗剂,其对NK1和NK2受体的Ki值分别为 230 nM 和8150 nM。Spantide I可减少感染角膜的1型细胞因子和增强2型细胞因子IL-10,从而显著减少角膜穿孔。
生物活性

Spantide I TFA, a substance P analog, is a selectiveNK1receptorantagonist, withKivalues of 230 nM and 8150 nM for NK1and NK2receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokineIL-10in the infected cornea, leading to a significant reduction in corneal perforation[1][2][3].

体内研究
(In Vivo)

Spantide I (50 and 100 nM perfused through the cerebral ventricles) causes a complete respiratory arrest in all of the examined animals[2].
Spantide I (36 μg/mouse, ip daily) significantly decreases the number of perforated corneas, bacterial counts, and PMNs. Spantide I also downregulates the mRNA levels for type I cytokines (e.g., IFN-γ) as well as MIP-2, IL-6, TNF-α, and IL-1β[3].

Animal Model:Female, 8-week-old C57BL/6 (B6) and BALB/c mice[3].
Dosage:36 μg/mouse.
Administration:IP on days -1 and 0 (day of infection) and daily through 5 days pi (post infection).
Result:At 3 and 5 days pi, compound-treated mice had significantly less severe ocular disease than did the PBS-treated mice.
Contained significantly fewer PMNs than the corneas of PBS-treated mice at 3 and 5 days pi.
Significantly reduced levels of corneal TNF-α mRNA at 3 and 5 days pi.
Significantly reduced the level of IL-18 mRNA at 1 day pi.
分子量

1611.81

Formula

C77H109F3N20O15

Sequence Shortening

{D-Arg}-PKPQQ-{D-Trp}-F-{D-Trp}-LL-NH2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent & Solubility
In Vitro: 

H2O

Peptide Solubility and Storage Guidelines:

1.  Calculate the length of the peptide.

2.  Calculate the overall charge of the entire peptide according to the following table:

 ContentsAssign value
Acidic amino acidAsp (D), Glu (E), and the C-terminal -COOH.-1
Basic amino acidArg (R), Lys (K), His (H), and the N-terminal -NH2+1
Neutral amino acidGly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q)0

3.  Recommended solution:

Overall charge of peptideDetails
Negative (<0)1.  Try to dissolve the peptide in water first.
2.  If water fails, add NH4OH (<50 μL).
3.  If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0)1.  Try to dissolve the peptide in water first.
2.  If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.  If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0)1.  Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.  For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.